Moderna on Monday announced its experimental vaccine against COVID-19 was shown to be 94.5% effective according to early results from a clinical trial with more than 30,000 participants. “This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease,” said Stephane Bancel, Moderna’s CEO.